Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire May Spin Out Neuroscience Unit To Tighten Rare Disease Focus

Executive Summary

The merger with Baxalta left Shire a portfolio consisting of 80% rare disease therapies, suggesting logically that the company might want to exit the primary care ADHD space.

Advertisement

Related Content

FDA's NDA And BLA Approvals: Cotempla XR-ODT, Baxdela, Mydayis, Rituxan Hycela, Haegarda
Shire CEO: Mydayis To Be Big ADHD Drug, But No Ex-US Launch Planned (Yet)
Shire's Ornskov On Goals And Accomplishments One Year After Baxalta Merger
Bioverativ Fills Gap In Pipeline With $400m True North Buy
Shire's Record Year Bolstered By Baxalta, But Shows Across-The-Board Growth
Shire’s Sales, R&D Heads Shed Light On The Post-Baxalta Road Ahead
Shire Plays Up Xiidra Launch, Downplays Missed Sales Expectations

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC099261

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel